 |
|
|
|
Epzicom |
|
Detailed Prescribing Information |
|
July 2006 |
|
Epzicom A combination of lamivudine + abacavir Approved 8-2-2004 |
|
| Forms Available | 300 mg lamivudine / 600 mg abacavir in tablets |
| Dosing | 1 tablet once a day |
| Renal dosing: not recommended for Ccr < 50 cc/min | |
| Hepatic dosing: not recommended for hepatic failure | |
| Food dependence | Epzicom may be taken with or without food. |
| Adverse Effects |
Same as
lamivudine plus
abacavir (see
above or click on the drug name) 5%
incidence of abacavir hypersensitivity, usually within the first six weeks
of therapy |
| Interactions | Same as lamivudine plus abacavir (see above or click on the drug name) |
| Suggested lab follow-up |
Monthly CBC, comprehensive metabolic profile for
3 months, then every 3 months if
stable Consider serum lactic acid level for symptoms of lactic acidosis (fatigue, nausea, anion gap acidosis, etc.) |
| Warning |
5-8% incidence of
abacavir hypersensitivity
(see abacavir above) The incidence of abacavir hypersensitivity is slightly higher (8%) with single daily dosing of abacavir in this formulation.
Rare lactic acidosis and hepatic
steatosis. Severe acute exacerbations of chronic hepatitis B may be observed with sudden discontinuation of Epzicom. |
| Contraindication | Previous abacavir hypersensitivity |
|
Suggested administration protocol |
Click HERE to review abacavir administration protocol |
|
Suggested Usage |
Do not use in combination with
lamivudine,
emtricitabine,
Truvada,
Combivir,
Atripla,
or
Trizivir due to identical mechanism of
action or duplication of
lamivudine dosing. Do not discontinue abruptly in patients with chronic hepatitis B without consideration of continuation of lamivudine or some other agent active against hepatitis B. |
|
Complete prescribing information |
Epzicom Prescribing Info |
| Links to Antiretroviral Sections (click on anything) |
| Nucleoside & Nucleotide Reverse Transcriptase Inhibitors (NRTI) |
| AZT | ddC | ddI | d4T | 3TC | ABC | FTC | TDF | Combivir | Trizivir | Epzicom | Truvada | Atripla |
| Nonnucleoside Reverse Transcriptase Inhibitors (NNRTI) |
| efavirenz | nevirapine | delavirdine |
| Protease Inhibitors (PI) | Boosted Protease Inhibitors |
| saquinavir | indinavir | ritonavir | nelfinavir | amprenavir | lopinavir + ritonavir | atazanavir | fosamprenavir | tipranavir | darunavir |
| Fusion Inhibitors |
| enfuvirtide |
Updated 7.14.2006
1. Renal dosing information from: Ian R.
McNicholl & Rudolph A. Rodriguez, MD, Dosing of Antiretroviral Drugs in Renal
Insufficiency and Hemodialysis, May 2004
http://hivinsite.ucsf.edu/InSite?page=md-rr-18
